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BACKGROUND
Data from randomized trials are lacking on the benefits and risks of initiating 
antiretroviral therapy in patients with asymptomatic human immunodeficiency 
virus (HIV) infection who have a CD4+ count of more than 350 cells per cubic 
millimeter.
METHODS
We randomly assigned HIV-positive adults who had a CD4+ count of more than 
500 cells per cubic millimeter to start antiretroviral therapy immediately (imme-
diate-initiation group) or to defer it until the CD4+ count decreased to 350 cells 
per cubic millimeter or until the development of the acquired immunodeficiency 
syndrome (AIDS) or another condition that dictated the use of antiretroviral 
therapy (deferred-initiation group). The primary composite end point was any seri-
ous AIDS-related event, serious non–AIDS-related event, or death from any cause.
RESULTS
A total of 4685 patients were followed for a mean of 3.0 years. At study entry, the 
median HIV viral load was 12,759 copies per milliliter, and the median CD4+ 
count was 651 cells per cubic millimeter. On May 15, 2015, on the basis of an 
interim analysis, the data and safety monitoring board determined that the study 
question had been answered and recommended that patients in the deferred-initi-
ation group be offered antiretroviral therapy. The primary end point occurred in 
42 patients in the immediate-initiation group (1.8%; 0.60 events per 100 person-
years), as compared with 96 patients in the deferred-initiation group (4.1%; 1.38 
events per 100 person-years), for a hazard ratio of 0.43 (95% confidence interval 
[CI], 0.30 to 0.62; P<0.001). Hazard ratios for serious AIDS-related and serious 
non–AIDS-related events were 0.28 (95% CI, 0.15 to 0.50; P<0.001) and 0.61 (95% 
CI, 0.38 to 0.97; P = 0.04), respectively. More than two thirds of the primary end 
points (68%) occurred in patients with a CD4+ count of more than 500 cells per 
cubic millimeter. The risks of a grade 4 event were similar in the two groups, as 
were the risks of unscheduled hospital admissions.
CONCLUSIONS
The initiation of antiretroviral therapy in HIV-positive adults with a CD4+ count 
of more than 500 cells per cubic millimeter provided net benefits over starting 
such therapy in patients after the CD4+ count had declined to 350 cells per cubic 
millimeter. (Funded by the National Institute of Allergy and Infectious Diseases 
and others; START ClinicalTrials.gov number, NCT00867048.)
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The immune compromise caused by the human immunodeficiency virus (HIV) is characterized by a loss of CD4+ T cells. 
Rates of HIV-associated complications and death 
increase as the number of these cells in peripheral 
blood (CD4+ count) declines.1-3 It has been general 
practice to defer the initiation of antiretroviral 
therapy in asymptomatic patients with a CD4+ 
count above a certain threshold level. The appli-
cable threshold has changed over time, and rec-
ommendations remain inconsistent across various 
guidelines.4
Randomized studies that have assessed the 
benefits and risks of treating patients with HIV 
infection sooner rather than later have largely 
enrolled patients with a CD4+ count of less than 
500 cells per cubic millimeter. In such studies, 
“later” has been defined as a CD4+ count of 200 
or 250 cells per cubic millimeter.5-8 These data, 
along with observational studies, provide strong 
evidence for the initiation of antiretroviral ther-
apy in patients with a CD4+ count of 350 cells per 
cubic millimeter.
Evidence for initiating antiretroviral therapy 
in patients with a CD4+ count of more than 350 
cells per cubic millimeter comes mainly from the 
results of observational studies.9-13 However, the 
findings of these studies are inconsistent and 
are subject to residual confounding.14-16 Further-
more, most studies have focused only on the risks 
of the acquired immunodeficiency syndrome 
(AIDS) and death and have not fully addressed 
the risks and benefits of initiating antiretroviral 
therapy in patients with a high CD4+ count, in 
whom complications and death are largely at-
tributed to non–AIDS-related events.17,18 Some 
studies have raised concern about the adverse ef-
fects of antiretroviral therapy on cardiovascular 
and renal disease,19,20 particularly in an aging HIV-
positive population. However, in an earlier large, 
randomized study, the continuous use of anti-
retroviral therapy, as compared with intermittent 
therapy, reduced these risks.17,18
Given the small absolute risk of AIDS among 
patients with a high CD4+ count, it is important 
to establish whether it is safe and beneficial to 
initiate antiretroviral therapy in asymptomatic 
patients who have a CD4+ count that is much 
higher than 350 cells per cubic millimeter. This 
information is particularly important given the 
known benefits of antiretroviral therapy in re-
ducing infectivity.7,21-24
In response to this gap in evidence, we designed 
a multicontinental randomized study, Strategic 
Timing of Antiretroviral Therapy (START), to de-
termine the risks and benefits of the immediate 
initiation of antiretroviral therapy in asymptom-
atic HIV-positive patients who have a CD4+ count 
of more than 500 cells per cubic millimeter, as 
compared with deferring initiation until the CD4+ 
count is 350 cells per cubic millimeter.
Me thods
The START trial was designed and conducted by 
the International Network for Strategic Initia-
tives in Global HIV Trials (INSIGHT). A descrip-
tion of the contributions of the study members 
is provided in Section 2 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org.
Study Patients
HIV-positive patients who were 18 years of age or 
older and who had not yet initiated antiretroviral 
therapy, had no history of AIDS, and were in gen-
erally good health were eligible for the study if they 
had had two CD4+ counts of more than 500 cells 
per cubic millimeter at least 2 weeks apart within 
60 days before enrollment. Women who were 
pregnant or breast-feeding at screening were not 
eligible; women who became pregnant during 
follow-up remained in the study. (For full details 
regarding the study design, see the study protocol, 
available at NEJM.org.) The study was approved 
by the institutional review board or ethics com-
mittee at each participating site, and written in-
formed consent was obtained from all patients.
Study Design
We evaluated two strategies for initiating anti-
retroviral therapy: immediate initiation and de-
ferred initiation until the CD4+ count declined 
to 350 cells per cubic millimeter or the development 
of an AIDS-related event or another condition 
that dictated the use of antiretroviral therapy (e.g., 
pregnancy).25,26 When the study was initiated in 
2009, the deferral strategy was consistent with 
recommendations in most treatment guidelines.27-30 
During the course of the study, some treatment 
guidelines changed. Because the evidence prompt-
ing these changes was limited, we did not revise 
the deferred-initiation strategy in our study.
The study protocol required the use of an ap-
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proved drug combination derived from the guide-
lines of the Department of Health and Human 
Services as the first antiretroviral regimen in the 
two study groups (Section 3 in the Supplementary 
Appendix).27
Study End Points
The primary end point was a composite outcome 
that included two major components. The first 
was any serious AIDS-related event, which includ-
ed death from AIDS or any AIDS-defining event 
(as outlined in the 1993 expanded surveillance 
document of the Centers for Disease Control and 
Prevention),31 with the exception of nonfatal 
herpes simplex virus infection and esophageal 
candidiasis, which were not counted because of 
their lesser severity. Hodgkin’s lymphoma was 
also counted as a serious AIDS-related event. The 
second component was any serious non–AIDS-
related event, including death from causes other 
than AIDS. Serious non–AIDS-related events con-
sisted of the following conditions: cardiovascular 
disease (myocardial infarction, stroke, or coro-
nary revascularization) or death from cardiovas-
cular disease, end-stage renal disease (initiation 
of dialysis or renal transplantation) or death 
from renal disease, liver disease (decompensated 
liver disease) or death from liver disease, non–
AIDS-defining cancer (except for basal-cell or 
squamous-cell skin cancer) or death from cancer, 
and any death not attributable to AIDS.
An end-point review committee whose mem-
bers were unaware of study-group assignments 
reviewed all reported serious AIDS-related and 
serious non–AIDS-related events and deaths using 
preestablished criteria.32 Events that the commit-
tee considered to be confirmed or probable were 
counted as end points.33,34
Secondary end points included serious AIDS-
related events, serious non–AIDS-related events, 
death from any cause, grade 4 events, and un-
scheduled hospitalizations for reasons other than 
AIDS. Grade 4 events were defined as potentially 
life-threatening symptomatic events not attrib-
utable to AIDS that required a medical interven-
tion.35 Grade 4 events and unscheduled hospital-
izations (also referred to as “other serious clinical 
events”) were reported regardless of antiretroviral-
therapy use or of any perceived association with 
antiretroviral therapy and were categorized accord-
ing to codes used in the Medical Dictionary for Regu-
latory Activities, version 18.0.
The design and data collection plan for START 
have been reported previously.25 Key features, 
including a summary of a planned sample-size 
reestimation in February 2013, are provided in 
Section 4 in the Supplementary Appendix.
Interim Monitoring
Study investigators were unaware of interim sum-
mary results throughout the study. An independent 
data and safety monitoring board reviewed the 
results of interim analyses. An O’Brien–Fleming 
boundary and the Lan–DeMets spending function 
based on information time (fraction of primary 
events accrued) were used to adjust for a type I er-
ror in the analysis of the primary end point.36,37 The 
data and safety monitoring board was also asked 
to consider the consistency of findings for the two 
major components of the primary end point, seri-
ous AIDS-related and serious non–AIDS-related 
events, before making a recommendation to stop 
or modify the study. Consistency was specified as 
treatment hazard ratios for each component favor-
ing the same treatment group, with a z statistic of 
more than 1.5.
On May 15, 2015, the board informed the 
National Institute of Allergy and Infectious Dis-
eases (NIAID) and the study leadership that the 
primary question of the study had been answered 
and recommended that the findings be immedi-
ately disseminated. The board also recommend-
ed offering antiretroviral therapy to patients in 
the deferred-initiation group who were not re-
ceiving antiretroviral therapy and continuing to 
follow the study patients. By the time of this 
review, approximately 60% of the planned 213 
primary events had occurred. On May 27, 2015, 
the study team leaders and NIAID notified in-
vestigators and patients of the findings.
Statistical Analysis
We compared the two study groups according to 
the intention-to-treat principle. We used time-to-
event methods, including Kaplan–Meier survival 
curves and Cox proportional-hazards models, to 
compare the two groups for the primary end point, 
its two major components, death from any cause, 
and other serious clinical events. Follow-up was 
censored on May 26, 2015, or the date of last 
study contact.
For the primary end point, hazard ratios and 
95% confidence intervals were estimated from a 
Cox model stratified according to six geographic 
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on March 21, 2017. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;9 nejm.org August 27, 2015798
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
regions (Africa, Europe and Israel, North Amer-
ica, South America and Mexico, Australia, and 
Asia) with a single binary indicator (immediate 
vs. deferred therapy). The proportional-hazards 
assumption was tested by including an interac-
tion term between the randomized treatment 
indicator and log-transformed follow-up time.
We performed sensitivity analyses to assess 
the effects of the diagnostic certainty of events 
and of missing data (Section 5 in the Supple-
mentary Appendix). The primary end point was 
also summarized for subgroups that were cate-
gorized according to eight predefined baseline 
characteristics. Heterogeneity of the treatment 
effect across subgroups was assessed by includ-
ing terms for interactions between treatment and 
subgroup variables in expanded Cox models. 
Results of subgroup analyses should be inter-
preted with caution because there was no adjust-
ment made for the type I error for the number 
of subgroups examined, and the statistical pow-
er was limited for subgroup analyses. Kaplan–
Meier estimates were used to describe the time 
until the initiation of antiretroviral therapy. We 
compared the two study groups for changes in 
the CD4+ count from study entry through fol-
low-up using longitudinal mixed models with 
random intercepts. Descriptive analyses (number 
and rate of primary end point) were performed 
for accumulated person-years within strata of 
specific, time-updated (latest) CD4+ counts dur-
ing follow-up. Statistical analyses were per-
formed with the use of SAS software, version 9.3 
(SAS Institute). All P values are two-sided.
R esult s
Study Patients
From April 2009 through December 2013, we 
randomly assigned 4685 patients to receive im-
mediate antiretroviral therapy (2326 patients) or 
deferred antiretroviral therapy (2359 patients) at 
215 sites in 35 countries38 (Section 1 in the 
Supplementary Appendix). The two study groups 
were well balanced at baseline (Table 1). The 
median age was 36 years, and 27% of the pa-
tients were women. The median CD4+ count 
was 651 cells per cubic millimeter, with counts 
as high as 2296 cells per cubic millimeter. The 
median HIV RNA viral load was 12,759 copies 
per milliliter.
Follow-up
The mean follow-up time was 3.0 years, and the 
median was 2.8 years (interquartile range, 2.1 to 
3.9); 23% of the patients were followed for more 
than 4 years. On May 26, 2015, the status with 
regard to the primary end point was unknown 
(which was defined as a lack of contact for at 
least 10 months) for 93 patients (4.0%) in the 
immediate-initiation group and 119 (5.0%) in 
the deferred-initiation group (Fig. S1 in the 
Supplementary Appendix).
Use of Antiretroviral Therapy, HIV RNA Levels, 
and CD4+ Counts
As of May 26, 2015, antiretroviral therapy had 
been started in 98% of patients in the immedi-
ate-initiation group and in 48% of those in the 
deferred-initiation group. The median CD4+ 
count at the time of the initiation of antiretrovi-
ral therapy in the deferred-initiation group was 
408 cells per cubic millimeter. Reasons for start-
ing antiretroviral therapy in the deferred-initia-
tion group are provided in Table S1 in the Sup-
plementary Appendix.
Patients received antiretroviral therapy for 
94% of the total follow-up time accrued in the 
immediate-initiation group and for 28% in the 
deferred-initiation group. The median time until 
the initiation of antiretroviral therapy in the 
deferred-initiation group was 3 years (Fig. 1A, 
and Fig. S2 in the Supplementary Appendix). 
Drugs that were primarily used for initial treat-
ment in the immediate-initiation group and the 
deferred-initiation group were tenofovir (89% in 
the two groups), emtricitabine (89% and 88%, 
respectively), and efavirenz (73% and 51%, re-
spectively) (Table S2 in the Supplementary Ap-
pendix).
The percentage of patients who had an HIV 
RNA level of 200 copies per milliliter or less dur-
ing follow-up mirrored the percentage who were 
receiving antiretroviral therapy (Fig. 1A). The 
median HIV RNA level at time of the initiation 
of antiretroviral therapy was lower in the imme-
diate-initiation group than in the deferred-initi-
ation group (13,462 and 41,525 copies per mil-
liliter, respectively), but the percentages of 
patients with full viral suppression by 12 months 
after initiation were similar (98% vs. 97%).
Average CD4+ counts increased markedly dur-
ing the first year after randomization in the 
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immediate-initiation group and continued to 
gradually increase thereafter (Fig. 1B). Converse-
ly, in the deferred-initiation group, average CD4+ 
counts decreased during the first year and then 
stabilized and subsequently increased slightly as 
more patients started to receive antiretroviral 
therapy. During the follow-up period, the average 
CD4+ count was 194 cells per cubic millimeter 
higher in the immediate-initiation group than in 
the deferred-initiation group (Fig. S3 in the 
Supplementary Appendix).
Study End Points
The composite primary end point was reported 
in 42 patients in the immediate-initiation group 
and in 96 in the deferred-initiation group (Table 2 
Characteristic
Immediate-Initiation 
 Group 
(N = 2326)
Deferred-Initiation 
 Group 
(N = 2359)
All Patients 
(N = 4685)
Median age (IQR) — yr 36 (29–44) 36 (29–44) 36 (29–44)
Female sex — no. (%) 624 (26.8) 633 (26.8) 1,257 (26.8)
Race or ethnic group — no. (%)†
Asian 198 (8.5) 190 (8.1) 388 (8.3)
Black 702 (30.2) 708 (30.0) 1,410 (30.1)
Latino or Hispanic 320 (13.8) 318 (13.5) 638 (13.6)
White 1,015 (43.6) 1,071 (45.4) 2,086 (44.5)
Other 91 (3.9) 72 (3.1) 163 (3.5)
Geographical region — no. (%)
Africa 499 (21.5) 501 (21.2) 1,000 (21.3)
Asia 179 (7.7) 177 (7.5) 356 (7.6)
Australia 56 (2.4) 53 (2.2) 109 (2.3)
Europe and Israel 763 (32.8) 776 (32.9) 1,539 (32.8)
North America 248 (10.7) 259 (11.0) 507 (10.8)
South America and Mexico 581 (25.0) 593 (25.1) 1,174 (25.1)
Mode of infection with HIV — no. (%)
Sexual contact
Men having sex with men 1,300 (55.9) 1,286 (54.5) 2,586 (55.2)
With person of opposite sex 873 (37.5) 917 (38.9) 1,790 (38.2)
Injection-drug use 37 (1.6) 27 (1.1) 64 (1.4)
Blood products, other, or unknown 116 (5.0) 129 (5.5) 245 (5.2)
Median time since HIV diagnosis (IQR) 
— yr
1.0 (0.4–3.0) 1.1 (0.4–3.1) 1.0 (0.4–3.1)
Median CD4+ count (IQR) —  
cells/mm3‡
651 (585–765) 651 (582–764) 651 (584–765)
Median HIV RNA (IQR) — copies/ml 13,000 
 (3133–43,808)
12,550 
 (2963–42,567)
12,759 
 (3019–43,391)
Current smoker — no. (%) 730 (31.4) 766 (32.5) 1,496 (31.9)
Median CHD risk at 10 yr (IQR) — %§ 1.9 (0.5–5.0) 1.9 (0.5–5.3) 1.9 (0.5–5.1)
*  There were no significant differences between the two groups at baseline. HIV denotes human immunodeficiency virus, 
and IQR interquartile range.
†  Race or ethnic group was self-reported.
‡  The median CD4+ count is based on an average of two CD4+ counts for each patient obtained at screening.
§  The 10-year risk of coronary heart disease (CHD) was calculated with the use of the risk-assessment tool from the 
Framingham Heart Study.
Table 1. Characteristics of the Patients at Baseline.*
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and Fig. 2A). The estimated hazard ratio in the 
immediate-initiation group, as compared with 
the deferred-initiation group, was 0.43 (95% con-
fidence interval [CI], 0.30 to 0.62; P<0.001) and 
did not vary significantly during the follow-up 
period (P = 0.77 by proportional-hazards testing). 
Sensitivity analyses showed similar estimates for 
the hazard ratio (Section 5 in the Supplementary 
Appendix).
Among the individual events included in the 
composite primary end point, the three most 
common events in the immediate-initiation group 
and the deferred-initiation group were cardio-
vascular disease (29% and 15%, respectively), 
non–AIDS-defining cancer (21% and 19%, respec-
tively), and tuberculosis (14% and 20%, respec-
tively) (Table S3 in the Supplementary Appendix). 
Of the 42 primary end points, only 4 (10%) oc-
curred before the initiation of antiretroviral 
therapy in the immediate-initiation group, as 
compared with 68 of 96 (71%) in the deferred-
initiation group.
In the comparison between the immediate-
initiation group and the deferred-initiation group, 
the estimated hazard ratio was 0.28 (95% CI, 
0.15 to 0.50; P<0.001) for a serious AIDS-related 
event, 0.61 (95% CI, 0.38 to 0.97; P = 0.04) for a 
serious non–AIDS-related event, and 0.58 (95% 
CI, 0.28 to 1.17; P = 0.13) for death from any 
cause (Table 2 and Fig. 2B, 2C, and 2D). Of the 
33 deaths, 20 (61%) were attributable to causes 
other than AIDS, cardiovascular disease, renal 
disease, liver disease, or cancer (Table S4 in the 
Supplementary Appendix).
Hazard ratios for the three most frequent 
serious AIDS-related events (tuberculosis, Kaposi’s 
sarcoma, and malignant lymphomas) are pro-
vided in Table 2. Most of the tuberculosis events 
(16 of 26) occurred in patients living in Africa. 
For the two most frequent serious non–AIDS-
Figure 1. Antiretroviral Therapy, HIV RNA Suppres-
sion, and CD4+ Count.
Shown are the percentages of patients who were re-
ceiving antiretroviral therapy (ART) and the percentag-
es of patients who had an HIV RNA level of less than 
200 copies per milliliter (Panel A) and the mean CD4+ 
count (Panel B) in the immediate-initiation group and 
the deferred-initiation group over a 5-year period. The 
vertical lines around the data points in Panel B indi-
cate 95% confidence intervals. Once ART was initiat-
ed, appropriate changes in regimens were mandated 
in cases of treatment-limiting adverse drug reactions 
or if the existing regimen did not fully suppress viral 
replication. Additional details regarding study-speci-
fied initial regimens of antiretroviral therapy and the 
frequency of specific antiretroviral drugs that were 
used in the initial regimens are provided in Section 3 
and Table S2 in the Supplementary Appendix.
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End Point
Immediate-Initiation  
Group 
(N = 2326)
Deferred-Initiation  
Group 
(N = 2359)
Hazard Ratio  
(95% CI)† P Value
no.
no./100  
person-yr no.
no./100  
person-yr
Composite primary end point 42 0.60 96 1.38 0.43 (0.30–0.62) <0.001
Components of the primary end 
point
Serious AIDS-related event 14 0.20 50 0.72 0.28 (0.15–0.50) <0.001
Serious non–AIDS-related 
event
29 0.42 47 0.67 0.61 (0.38–0.97) 0.04
Death from any cause 12 0.17 21 0.30 0.58 (0.28–1.17) 0.13
Tuberculosis 6 0.09 20 0.28 0.29 (0.12–0.73)  0.008
Kaposi’s sarcoma 1 0.01 11 0.16 0.09 (0.01–0.71) 0.02
Malignant lymphoma 3 0.04 10 0.14 0.30 (0.08–1.10) 0.07
Cancer not related to AIDS 9 0.13 18 0.26 0.50 (0.22–1.11) 0.09
Cardiovascular disease 12 0.17 14 0.20 0.84 (0.39–1.81) 0.65
Other secondary end points
Grade 4 event‡ 73 1.06 73 1.05 1.01 (0.73–1.39) 0.97
Unscheduled  
hospitalization§
262 4.02 287 4.40 0.91 (0.77–1.08) 0.28
Grade 4 event, unscheduled 
hospitalization, or death 
from any cause
283 4.36 311 4.78 0.91 (0.77–1.07) 0.25
Most common grade 4 events, 
unscheduled hospitaliza-
tion, or death from any 
cause¶
Bacterial infectious disorder 14 0.20 36 0.52 0.38 (0.20–0.70)  0.002
Bone or joint injury 17 0.24 11 0.16 1.55 (0.73–3.31) 0.26
Depressed mood disorder or 
disturbance
12 0.17 9 0.13 1.34 (0.57–3.19) 0.50
Infection with unspecified 
pathogen
64 0.93 65 0.94 0.99 (0.70–1.40) 0.96
Injury not elsewhere 
 classified
11 0.16 22 0.31 0.50 (0.24–1.03) 0.06
Suicidal or self-injurious  
behavior not elsewhere 
classified
27 0.39 24 0.34 1.15 (0.66–1.99) 0.63
Viral infectious disorder 12 0.17 15 0.21 0.81 (0.38–1.72) 0.58
Grade 4 event, unscheduled 
 hospitalization, or pri- 
mary end point
295 4.56 355 5.52 0.82 (0.71–0.96) 0.01
*  The primary end point was a composite of serious AIDS-related and serious non–AIDS-related events, including death 
from any cause. Person-years differ for each row since the “time to first event” differs slightly according to event type. 
The numbers of serious AIDS-related and serious non–AIDS-related events do not sum to the total number of primary 
events because one patient in each group had a serious AIDS-related event first and later died from causes other than 
AIDS (a serious non–AIDS-related event). Additional details regarding the full composition of the primary end point are 
provided in Table S3 in the Supplementary Appendix.
†  The hazard ratio is for the immediate-initiation group as compared with the deferred-initiation group.
‡  Listed are symptomatic grade 4 events, according to the Division of AIDS (DAIDS) Table for Grading the Severity of 
Adult and Pediatric Adverse Events.35
§  This category excludes hospitalizations for AIDS-related illnesses.
¶  The cited subcategories of grade 4 events, unscheduled hospitalizations, or deaths from any cause are high-level group 
terms from the Medical Dictionary for Regulatory Activities, version 18.0, that were reported in at least 20 patients in the 
two study groups.
Table 2. Primary and Secondary End Points.*
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Figure 2. Primary and Secondary End Points.
Shown are Kaplan–Meier estimates of the cumulative percentages of patients with the composite primary end point  
(a serious AIDS-related or serious non–AIDS-related event, including death) in the two study groups (Panel A). 
 Secondary end points included serious AIDS-related events (Panel B), serious non–AIDS-related events (Panel C), 
death from any cause (Panel D), and grade 4 events (Panel E). Grade 4 events were defined as potentially life-
threatening symptomatic events that were not attributable to AIDS and that required medical intervention.
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related events (non-AIDS cancer and cardiovas-
cular disease), the estimated hazard ratios were 
0.50 (95% CI, 0.22 to 1.11; P = 0.09) and 0.84 
(95% CI, 0.39 to 1.81; P = 0.65), respectively. Most 
of the cancers and cardiovascular events occurred 
in patients from Australia, Europe, Israel, and the 
United States (22 of 27 and 19 of 26, respectively). 
The hazard ratio for cancer (combining AIDS 
and non-AIDS cancers) was 0.36 (95% CI, 0.19 to 
0.66; P = 0.001). (Table S3 in the Supplementary 
Appendix summarizes the types of cancer.)
Other Serious Clinical Events
Symptomatic grade 4 events occurred in 73 pa-
tients in each study group (hazard ratio, 1.01; 
95% CI, 0.73 to 1.39; P = 0.97) (Table 2 and Fig. 2E). 
Unscheduled hospitalizations for reasons other 
than events associated with AIDS progression 
occurred in 262 patients in the immediate-initi-
ation group and 287 in the deferred-initiation 
group (hazard ratio, 0.91; 95% CI, 0.77 to 1.08; 
P = 0.28) (Table 2). In an analysis of the most 
common types of events in a composite end 
point of grade 4 events, unscheduled hospitaliza-
tions, or death, the rate of bacterial infections was 
significantly reduced in the immediate-initiation 
group (P=0.002); rates of other common events 
did not differ significantly between the groups. 
For a composite end point that included grade 4 
events, unscheduled hospitalizations, and the pri-
mary end point as an overall measure of clinical 
benefit, there were 295 patients in the immediate-
initiation group and 355 in the deferred-initia-
tion group who had an event (hazard ratio, 0.82; 
95% CI, 0.71 to 0.96; P = 0.01). Sixteen suspected, 
unexpected serious adverse reactions were report-
ed among patients receiving antiretroviral therapy 
(Table S5 in the Supplementary Appendix).
Subgroup Analyses
The study population was divided into subgroups 
according to characteristics at study entry, includ-
ing demographic measures and other risk factors 
for serious AIDS-related and serious non–AIDS-
related disease. Across all subgroups, hazard 
ratios consistently favored the immediate-initia-
tion group (Fig. 3).
Primary End Point According to Latest CD4+ 
Count
As intended, the percentage of follow-up time 
that patients spent in various categories of latest 
CD4+ count differed markedly according to study 
group (Fig. S4 in the Supplementary Appendix). 
In the two groups, the majority of primary events 
occurred when the CD4+ count was greater than 
500 cells per cubic millimeter, in 37 of 42 pa-
tients (88%; rate of 0.6 per 100 person-years) in 
the immediate-initiation group and in 57 of 96 
(59%; rate of 1.1 per 100 person-years) in the 
deferred-initiation group. The percentage of fol-
low-up time in which patients had a CD4+ count 
of more than 500 cells per cubic millimeter was 
94% in the immediate-initiation group and 72% 
in the deferred-initiation group. During this time 
with high latest CD4+ counts, antiretroviral 
therapy was administered for 95% of the person-
years accrued in the immediate-initiation group 
and for 27% of the person-years in the deferred-
initiation group.
Consistent with the planned deferral strategy, 
latest CD4+ counts were below 350 cells per cubic 
millimeter for only 4% of follow-up time in the 
deferred-initiation group. During this time, 5 pri-
mary events occurred (Fig. S4 in the Supplemen-
tary Appendix).
Discussion
In this large, international, randomized study 
involving previously untreated HIV-positive adults 
with a CD4+ count of more than 500 cells per 
cubic millimeter, the immediate initiation of 
antiretroviral therapy was superior to deferral of 
such therapy until the CD4+ count declined to 
350 cells per cubic millimeter. A beneficial effect 
of immediate antiretroviral therapy was evident 
for both serious AIDS-related and serious non–
AIDS-related events, and no increased rate of 
adverse effects associated with this strategy was 
observed. There was no evidence that the benefi-
cial effect of immediate antiretroviral therapy 
differed according to age, sex, race, region of the 
world, CD4+ count, viral load, or risk factors for 
serious non-AIDS diseases.
In contrast to our study, previous randomized 
studies enrolled patients with lower CD4+ counts 
and compared immediate antiretroviral therapy 
with deferred therapy when counts reached 250 
or 200 cells per cubic millimeter.5-8 These trials 
established that antiretroviral therapy should be 
started before the CD4+ count declined to 250 
cells per cubic millimeter. Since rates of AIDS-
related and non–AIDS-related events are low when 
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CD4+ counts are more than 500 cells per cubic 
millimeter (as demonstrated in this study), it was 
important that the risks and benefits of antiretro-
viral therapy should be reliably established be-
cause even unusual drug-related adverse events 
could offset reductions in AIDS-related events. 
In our study, the benefit of immediate antiretro-
viral therapy over deferred therapy was quanti-
fied, and safety was assessed across various 
outcomes, including a diverse set of non-AIDS 
conditions. Our results indicate that antiretroviral 
therapy should be recommended for patients in 
whom HIV has been diagnosed regardless of the 
CD4+ count.
Coupled with previous studies showing that 
antiretroviral therapy reduces the risk of sexual 
transmission of HIV,7,21 the results of our study 
provide policymakers, clinicians, and HIV-posi-
tive patients with data to inform policies regard-
ing the initiation of antiretroviral therapy. Pa-
tients may wish to consider and differently 
weigh multiple factors when making the deci-
sion with their clinician to initiate lifelong anti-
retroviral therapy. Although the relative reduction 
in the risk of the primary end point was large in 
the immediate-initiation group, the absolute dif-
ferences were fairly small for most subgroups, 
which may mean that some low-risk patients 
Figure 3. Subgroup Analyses for the Primary End Point.
For subgroups that were defined according to age, CD4+ count, HIV RNA level, and risk of coronary heart disease (CHD), the continu-
ous variables were used for interaction tests. For 71 patients (1.5%), the Framingham Heart Study risk of CHD could not be calculated 
because of missing data. Of the patients with missing data, the primary end point occurred in 2 in the deferred-initiation group.
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may still choose to defer antiretroviral therapy.39 
Conversely, some patients may want to start 
antiretroviral therapy primarily to reduce trans-
mission risk.39 The individual health benefit from 
antiretroviral therapy that is shown in this study 
should better inform such choices.
In designing this study, we hypothesized that 
immediate antiretroviral therapy would have a 
greater benefit for serious AIDS-related events 
than for serious non–AIDS-related events. The 72% 
relative reduction in serious AIDS-related events 
in the immediate-initiation group largely arose 
from reductions in rates of tuberculosis, Kaposi’s 
sarcoma, and malignant lymphomas, whereas 
the 39% relative reduction in serious non–AIDS-
related events was largely due to non–AIDS-
defining cancers. The effects of immediate anti-
retroviral therapy on AIDS and non-AIDS events 
were seen even though more patients in the de-
ferred-initiation group than we anticipated start-
ed antiretroviral therapy when they had a CD4+ 
count of more than 350 per cubic millimeter.25
Our findings have global relevance, since the 
study was conducted in 215 clinics in 35 coun-
tries and represents a broad population of HIV-
positive patients. Although specific outcomes dif-
fered according to geographic region, the benefits 
of immediate antiretroviral therapy were consis-
tent. Tuberculosis was more frequent in Africa, 
where the disease remains endemic, whereas 
cardiovascular disease and cancer were more 
frequent in higher-income countries. The benefit 
of immediate antiretroviral therapy across regions 
of the world indicates that controlling viral repli-
cation and improving immune function have 
broad positive effects.
The primary end point incorporated poten-
tially serious positive and negative effects of 
antiretroviral therapy, and no safety concerns in 
the immediate-initiation group were identified. 
Grade 4 events and unscheduled hospitalizations 
occurred more often than did the primary out-
come, but rates of these events were similar in 
the two study groups.
Most of the AIDS-related and non–AIDS-related 
events occurred when patients had a high CD4+ 
count. Immediate antiretroviral therapy benefited 
even those with a latest CD4+ count of more 
than 500 cells per cubic millimeter, which may 
indicate that a substantial part of the beneficial 
effect of immediate treatment is due to changes 
induced by antiretroviral therapy in markers other 
than the CD4+ count. This finding is consistent 
with the results of studies that were used as a 
basis for our study11,25 and with other large ob-
servational studies conducted both in resource-
rich and resource-poor settings.40,41
The risk of AIDS was not zero among patients 
receiving antiretroviral therapy, even among those 
who had full viral suppression while receiving 
antiretroviral drugs. This finding indicates that 
damage to the immune system may occur early 
in the course of HIV infection.42 It further sup-
ports the need for better markers of impaired 
immune function and research on treatments to 
use along with antiretroviral therapy to reduce 
disease among HIV-positive patients.
Our study has some limitations. The percent-
age of primary events that were attributable to 
serious non–AIDS-related conditions was lower 
than anticipated (54% vs. 77% projected), which, 
combined with the early termination of the de-
ferred-therapy strategy, resulted in a low statis-
tical power to precisely quantify benefit. This 
factor limits our understanding of the effects of 
immediate therapy on the risk of individual seri-
ous non-AIDS conditions such as cardiovascular 
disease, for which reductions might be antici-
pated because of reductions in coagulation and 
inflammatory markers.43,44 Further follow-up of 
this young cohort and analyses of intermediate 
markers45,46 may elucidate the effects of immedi-
ate antiretroviral therapy on arterial disease and 
other serious non-AIDS conditions. Finally, al-
though we conducted a relatively long study of 
HIV treatment, 3 years is a rather short period for 
patients who will require antiretroviral therapy 
for the rest of their lives. It will be important to 
assess risks and benefits of long-term therapy.
In conclusion, we found a significant benefit in 
the immediate initiation of antiretroviral therapy 
in patients with HIV infection regardless of CD4+ 
count. These results align benefits for individual 
patients with the public health benefit of anti-
retroviral therapy in reducing the risk of viral 
transmission. Our findings reinforce the need 
for health systems to improve programs to diag-
nose HIV infection and link such patients to care. 
The results support global goals set by the World 
Health Organization and the Joint United Nations 
Programme on HIV/AIDS to expand the use of 
antiretroviral therapy to all HIV-positive patients 
in order to improve their health and as part of 
efforts to reduce the future spread of HIV.22-24,47,48
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